Cite
HARVARD Citation
Zeng, L. et al. (2020). Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population. Lung cancer. pp. 82-88. [Online].